Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Peripheral Arterial Occlusive DiseaseCritical Limb Ischemia

Interventions

DRUG

[89Zr]Zr-DFO-APAC

All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).

RADIATION

PET/CT scan

The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.

Trial Locations (1)

RECRUITING

The University Medical Center Groningen, Groningen